Семаглутид в терапии сахарного диабета 2 типа: обзор накопленных данных от идеи создания до настоящего времени

В клинических рекомендациях все чаще подчеркивается важность многофакторного лечения диабета 2 типа (СД2), включающее как гликемический контроль, так и контроль массы тела, всестороннее управление классическими кардиологическими факторам риска, а также использование препаратов с доказанными кардионефропротективными эффектами для снижения риска долгосрочных осложнений.

Разработка семаглутида – длительно действующего и высокогомологичного агониста рецепторов глюкагоноподобного пептида-1 (арГПП-1) на основе широкопризнанного представителя класса лираглутида – явилась важной вехой в расширении возможностей управления заболеванием, а успехи, достигнутые в клинической исследовательской программе препарата, внесли свой вклад в формирование вышеуказанных аспектов рекомендаций.

Клиническая эффективность семаглутида оценивалась в рамках программы клинических исследований SUSTAIN на более чем 10000 пациентов с СД2. Программа включает 6 основных глобальных исследований фазы IIIа (SUSTAIN 1-6) и 5 исследований фазы IIIb (SUSTAIN 7-11), а также ряд других исследований и анализов.

Разработка отечественного воспроизведенного препарата, содержащего семаглутид, позволит увеличить доступность препаратов семаглутида в РФ, а также значительно более эффективно контролировать уровень гликемии у пациентов с СД2. В данном обзоре представлены результаты эффективности и безопасности семаглутида, включая российский биоэквивалентный препарат семаглутида.

1. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Арг 12;1О:155. https://doi.org/10.3389/fendo.2019.00155.

2. Aroda VR, Ahmann А, Cariou В, Chow F, Davies MJ, J6dar Е, Mehta R, Woo V, Lingvay 1. Comparative effi cacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: lnsights from the SUSTAIN 1–7 trials. Diabetes Metab. 2019 Oct;45(5):409–418. https://doi.org/10.1016/j.diabet.2018.12.001.

3. Goldenberg RM, Steen О. Semaglutide: Review and Place in Therapy for Adults With Туре 2 Diabetes. Сап J Diabetes. 2019 Маг;43(2):136–145. https://doi.org/10.1016/j.jcjd.2018.05.008.

4. Aroda VR, Capehorn MS, Chaykin L, Frias JP, Lausvig NL, Macura S, LUdemann J, Madsbad S, Rosenstock J, Tabak О, Tadayon S, Bain SC. lmpact of baseline characteristics and beta-cell function оп the effi cacy and safety of subcutaneous once-weekly semaglutide: А patientlevel, pooled analysis of the SUSTAIN 1–5 trials. Diabetes Obes Metab. 2020 Маг;22(3):303–314. https://doi.org/10.1111/dom.13896.

5. Warren М, Chaykin L, Trachtenbarg D, Nayak G, Wij ayasinghe N, Cariou В. Semaglutide as а therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1–5 trials. Diabetes Obes Metab. 2018 Sep;20(9):2291– 2297. https://doi.org/10.1111/dom.13331.

6. Mann, J. F. Е., Hansen, Т., ldorn, Т., Leiter, L. А., Marso, S. Р., Rossing, Р., Vilsb121II, Т. (2020). Eff ects of once-weekly subcutaneous semaglutide оп kidney function and safety in patients with type 2 diabetes: а post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213–8587(20)30313–2.

7. Cherney DZI, Hadjadj S, Lawson J, Mosenzon О, Tuttle К, Vrhnjak В, Rasmussen S, Bain SC. HemogloЬin А1с Reduction With the GLP-1 Receptor Agonist Semaglutide Is lndependent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs. Kidney lnt Rep. 2022 Aug 3;7(11):2345–2355. https://doi.org/10.1016/j.ekir.2022.07.167.

8. Lingvay 1, Hansen Т, Macura S, et al. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse eventsBMJ Open Diabetes Research and Саге 2020;8: е001706. https://doi.org/10.1136/bmjdrc-2020–001706.

9. Frfas JP, Auerbach Р, Bajaj HS, Fukushima У, Lingvay 1, Macura S, S121ndergaard AL, Tankova TI, Tentolouris N, Buse JB. Effi cacy and safety of once-weekly semaglutide 2–0 mg versus 1–0 mg in patients with type 2 diabetes (SUSTAIN FORTE): а douЫeЫind, randomised, phase 3В trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563–574. https://doi.org/10.1016/S2213–8587(21)00174–1.

10. Davies М, Faэrch L, Jeppesen ОК, Pakseresht А, Pedersen SD, Perreault L, Rosenstock J, Shimomura 1, Viljoen А, Wadden ТА, Lingvay 1; STEP 2 Study Group. Semaglutide 2–4 mg once а week in adults with overweight ог obesity, and type 2 diabetes (STEP 2): а randomised, douЫe-Ыind, douЫe-dummy, placebocontrolled, phase 3 trial. Lancet. 2021 Маг 13;397(10278):971–984. https://doi.org/10.1016/S0140–6736(21)00213–0.

11. Pratley RE, Aroda VR, Lingvay 1, LUdemann J, Andreassen С, Navarria А, Viljoen А; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): а randomised, open-label, phase 3Ь trial. Lancet Diabetes Endocrinol. 2018 Арг;6(4):275–286. https://doi.org/10.1016/S2213–8587(18)30024-Х.

12. Goldenberg, R., Pratley, R. Е., Aroda, V. R., Gondolf, Т., Hansen, Т., Lingvay, 1., LUdemann, J., Skj12.1th, Т. V., & Viljoen, А. (2019). 87 – Effi cacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Туре 2 Diabetes: Posthoc Analysis of SUSTAIN 7. ln Canadian Journal of Diabetes (Vol. 43, lssue 7, р. S32). Elsevier BV. https://doi.org/10.1016/j.jcjd.2019.07.096.

13. Frias JP, Bonora Е, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, Malik R, Bethel МА, Сох DA. Effi cacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin Treated Patients With Туре 2 Diabetes in а Randomized Controlled Trial (AWARD-11). Diabetes Саге. 2021 Маг;44(3):765–773. https://doi.org/10.2337/dc20–1473.

14. Pratley RE, Catarig АМ, Lingvay 1, Viljoen А, Paine А, Lawson J, Chubb В, Gorst-Rasmussen А, Miresashvili N. An indirect treatment comparison of the effi cacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obes Metab. 2021 Nov;23(11):2513–2520. https://doi.org/10.1111/dom.14497.

15. Lingvay 1, Bauer R, Baker-Knight J, Lawson J, Pratley R. An lndirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. J Clin Endocrinol Metab. 2022 Арг 19;107(5):1461–1469. https://doi.org/10.1210/clinem/dgab905.

16. Capehorn MS, Catarig АМ, Furberg JK, Janez А, Price НС, Tadayon S, Verges В, Магге М. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 1О). Diabetes Metab. 2020 Арг;46(2):100–109. https://doi.org/10.1016/j.diabet.2019.101117.

17. Lingvay 1, Catarig АМ, Frias JP, Kumar Н, Lausvig NL, le Roux CW, Thielke D, Viljoen А, McCrimmon RJ. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): а douЫeЫind, phase 3Ь, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Nov;7(11):834–844. https://doi.org/10.1016/S2213–8587(19)30311-О.

18. McCrimmon RJ, Catarig АМ, Frias JP, Lausvig NL, le Roux CW, Thielke D, Lingvay 1. Effects of once-weekly semaglutide vs once-daily canagliflozin оп body composition in type 2 diabetes: а substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020 Маг;63(3):473–485. https://doi.org/10.1007/s00125–019–05065–8.

19. Lingvay 1, Capehorn MS, Catarig АМ, Johansen Р, Lawson J, Sandberg А, Shaw R, Paine А. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Туре 2 Diabetes: Patient-Level Meta-analysis. J Clin Endocrinol Metab. 2020 Dec 1;105(12): е4593–604. https://doi.org/10.1210/clinem/dgaa577.

20. Zinman В, Bhosekar V, Busch R, Holst 1, Ludvik В, Thielke D, Thrasher J, Woo V, Philis-Tsimikas А. Semaglutide once weekly as add-on to SGLТ-2 inhiЬitor therapy in type 2 diabetes (SUSTAIN 9): а randomised, placebocontrolled trial. Lancet Diabetes Endocrinol. 2019 Мау;7(5):356–367. https://doi.org/10.1016/S2213–8587(19)30066-Х.

21. Kellerer М, Kaltoft MS, Lawson J, Nielsen LL, Strojek К, Tabak О, Jacob S. Effect of once-weekly semaglutide versus thricedaily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): А randomized, open-label, multinational, phase 3Ь trial. Diabetes Obes Metab. 2022 Sep;24(9):1788–1799. https://doi.org/10.1111/dom.14765.

22. Marso SP, Bain SC, Consoli А, Eliaschewitz FG, J6dar Е, Leiter LA, Lingvay 1, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen О, Holst AG, Pettersson J, Vilsb121II Т; SUSTAIN-6 lnvestigators. Semaglutide and Cardiovascular Outcomes in Patients with Туре 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141.

23. Strain WD, Frenkel О, James МА, Leiter LA, Rasmussen S, Rothwell РМ, Sejersten Ripa М, Truelsen ТС, Husain М. Effects of Semaglutide оп Stroke SuЫypes in Туре 2 Diabetes: Post Нос Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022 Sep;53(9):2749–2757. https://doi.org/10.1161/STROKEA-HA.121.037775.

24. Kolkailah, А. А., Lingvay, 1., Dobrecky-Mery, 1., Aharonovich, А., David, J., Holse, С., Rasmussen, S., & McGuire, О. К. (2022). Effects of once-weekly subcutaneous semaglutide оп coronary artery disease outcomes in patients with type 2 diabetes with ог at high risk for cardiovascular disease: lnsights from the SUSTAIN-6 trial. ln Diabetes, Obesity and Metabolism (Vol. 25, lssue 4, рр. 1117–1120). Wiley. https://doi.org/10.1111/dom.14941.

25. Leiter LA, Bain SC, Hramiak 1, J6dar Е, Madsbad S, Gondolf Т, Hansen Т, Holst 1, Lingvay 1. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: а post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019 Jun 6;18(1):73. https://doi.org/10.1186/s12933–019–0871–8.

26. Verma S, Bain SC, Monk Fries Т, Mazer CD, Nauck МА, Pratley RE, Rasmussen S, Saevereid НА, Zinman В, Buse JB. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: А post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2019 Jul;21(7):1745–1751. https://doi.org/10.1111/dom.13698.

27. Verma S, AI-Omran М, Leiter LA, Mazer CD, Rasmussen S, Saevereid НА, Sejersten Ripa М, Bonaca МР. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022 Jul;24(7):1288–1299. https://doi.org/10.1111/dom.14700.

28. Verma S, Bain SC, Honore JB, F Е Mann J, А Nauck М, Е Pratley R, Rasmussen S, Sejersten Ripa М, Zinman В, Buse JB. lmpact of microvascular disease оп cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2020 Nov;22(11):2193–2198. https://doi.org/10.1111/dom.14140.

29. Rossing Р, Bain SC, Bosch-Traberg Н, Sokareva Е, Heerspink HJL, Rasmussen S, MellЬin LG. Effect of semaglutide оп major adverse cardiovascular events Ьу baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis. Cardiovasc Diabetol. 2023 Aug 24;22(1):220. https://doi.org/10.1186/s12933–023–01949–7.

30. Verma S, David JP, Leiter LA, Michelsen ММ, Rasmussen S, Bhatt DL. Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials. Diabetes Obes Metab. 2023 Aug;25(8):2388–2392. https://doi.org/10.1111/dom.15081.

31. Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, Rasmussen S, Ripa MS, Vrazic Н, Verma S. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide оп cardiovascular and renal outcomes across baseline Ыооd pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Sep;22(9):1690–1695. https://doi.org/10.1111/dom.14079.

32. Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries Т, Pratley RE, Rasmussen S, Vrazic Н, Zinman В, Buse JB. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide оп cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Dec;22(12):2487– 2492. https://doi.org/10.1111/dom.14160.

33. L.G. MellЬin, D. L. Bhatt, J.-P. David, М. С. Petrie, S. Rasmussen, Р. А. Schytz, Т. Vilsb121I. Effect of semaglutide versus placebo оп cardiovascular outcomes Ьу baseline НЬА1с: SUSTAIN 6 and PIONEER 6 post hoc analysis. Session: SO 44 Lessons from trials. Oral Presentation # 594. Hybrid 58th EASD Annual Meeting. 2022. https://www.easd.org/media-centre/home.html#!resources/effect-of-semaglutide-versus-placebo-on-cardiovascular-outcomes-by-baseline-hba-sub1c–sub-sustain-6-and-pioneer-6-post-hoc-i-i-analysis.

34. Zobel ЕН, von Scholten BJ, Hansen TW, Persson F, Rasmussen S, Wolthers В, Rossing Р. The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2022 Feb;24(2):281–288. https://doi.org/10.1111/dom.14578.

35. Shaman АМ, Bain SC, Bakris GL, Buse JB, ldorn Т, Mahaffey KW, Mann JFE, Nauck МА, Rasmussen S, Rossing Р, Wolthers В, Zinman В, Perkovic V. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide оп Kidney Outcomes in Patients With Туре 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 Feb 22;145(8):575–585. https://doi.org/10.1161/CIRCULATIONAHA.121.055459.

36. Tuttle KR, Bosch-Traberg Н, Cherney DZI, Hadjadj S, Lawson J, Mosenzon О, Rasmussen S, Bain SC. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more staЫe kidney function compared with placebo. Kidney lnt. 2023 Арг;103(4):772–781. https://doi.org/10.1016/j.kint.2022.12.028.

37. Арефьева АН, Банко ВВ, Садовских МО, Носков СМ. Первый препарат семаглутида в Российской Федерации: результаты открытого рандомизированного исследования фармакокинетики. Медицинский совет. 2023;17(16): 77–82. https://doi.org/10.21518/ms2023–312.